Data / Form D filings / ViaCyte Inc.
ViaCyte Inc.: Form D filings
ViaCyte Inc., a biotechnology company in San Diego, CA, filed 5 Form D notices with the SEC between 2013 and 2021. The latest, on April 22, 2021, reports $53.9 million sold of a $58.5 million offering to 22 investors.
Find out what ViaCyte Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3550 GENERAL ATOMICS COURT, San Diego, CA, 92121
- Phone
- (858) 207-0500
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1581903
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 22, 2021 | New notice | $58,506,166 | $53,931,166 | $4,575,000 | 22 | Apr 6, 2021 | sec.gov |
| Apr 2, 2020 | New notice | $36,018,634 | $32,645,780 | $3,372,854 | 17 | Mar 20, 2020 | sec.gov |
| Dec 3, 2018 | New notice | $90,021,103 | $35,833,603 | $54,187,500 | 9 | Nov 16, 2018 | sec.gov |
| Aug 21, 2014 | New notice | $15,000,000 | $15,000,000 | $0 | 1 | Aug 8, 2014 | sec.gov |
| Jul 19, 2013 | New notice | $27,175,642 | $12,150,824 | $15,024,818 | 55 | Jul 8, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Amir R. Zamani | Director | |
| Brittany G. Bradrick | Executive Officer | |
| Sandra G. Poole | Director | |
| Anne G. Sandan | Executive Officer | |
| Elizabeth G. Bui | Executive Officer | |
| Lucian A. Iancovici | Director | |
| Steve G. White | Executive Officer | |
| Fred A. Middleton | Director | |
| Mark G. Foletta | Director | |
| Howard G. Foyt | Executive Officer | |
| Paul G. Hastings | Director | |
| Steven R. Altman | Director | |
| Ian G. Smith | Director | |
| Kevin G. D'Amour | Executive Officer | |
| Asish R. Xavier | Director | |
| Michael Yang | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
- Tempest Therapeutics, Inc. $7.5 million · Oct 14, 2026
- Lionheart Health, Inc. $387,500 · Oct 7, 2026
- Rakuten Medical, Inc. $9 million · Oct 6, 2026
- Zonaliz, Inc. $2.5 million · Oct 5, 2026
- Altay Therapeutics, Inc. $15.7 million · Oct 2, 2026
- Sialia Therapeutics, Inc. $1.5 million · Sep 29, 2026
- Vetmab Biosciences, Inc. $11.4 million · Sep 29, 2026
Every Form D from the week of Apr 19, 2021 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what ViaCyte Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.